18097958. Two-Phase Delivery Of Plasma simplified abstract (Velico Medical, Inc.)

Two-Phase Delivery Of Plasma

Organization Name

Velico Medical, Inc.

Inventor(s)

Richard Meehan of Caragh Co (IE)

Robert R. Andrews of Norfolk MA (US)

Herman E. Snyder of W. Lafayette IN (US)

William J. Merritt of Danvers MA (US)

Evan P. Ordway of Salem MA (US)

Clair Strohl of Emmaus PA (US)

Qiyong Peter Liu of Newton MA (US)

Jihae Sohn of Salem MA (US)

Two-Phase Delivery Of Plasma - A simplified explanation of the abstract

This abstract first appeared for US patent application 18097958 titled 'Two-Phase Delivery Of Plasma

Simplified Explanation

The present invention is a spray dried plasma composition with various desirable characteristics, including being largely amorphous, free of cholesterol crystals, reduced large particulates, low residual moisture, rapid reconstitution time, high stability under different storage conditions, recovery of fragile proteins, near normal plasma pH upon reconstitution, and reduced complement activation.

• Largely amorphous when reconstituted
• No cholesterol crystals present
• Reduced large particulates
• Low residual moisture
• Rapid reconstitution time
• High stability under different storage conditions
• Recovery of fragile proteins
• Near normal plasma pH upon reconstitution
• Reduced complement activation

Potential Applications

The technology could potentially be used in medical settings for emergency transfusions, in research laboratories for protein studies, and in pharmaceutical manufacturing for the production of plasma-derived products.

Problems Solved

This technology solves the problem of unstable plasma compositions, slow reconstitution times, and potential protein denaturation during storage and reconstitution.

Benefits

The benefits of this technology include improved stability, faster reconstitution, better protein recovery, and reduced complement activation, leading to more effective and reliable plasma products.

Potential Commercial Applications

The technology could find commercial applications in the pharmaceutical industry for the production of plasma-derived products, in medical settings for emergency transfusions, and in research laboratories for protein studies.

Possible Prior Art

One possible prior art could be the traditional methods of plasma drying and storage, which may not offer the same level of stability, protein recovery, and reduced complement activation as the present invention.

How does this technology compare to existing plasma drying methods in terms of cost-effectiveness?

The article does not provide information on the cost-effectiveness of this technology compared to traditional plasma drying methods.

What are the potential regulatory hurdles for implementing this technology in medical settings?

The article does not address the potential regulatory challenges that may arise when implementing this technology in medical settings.

Original Abstract Submitted

The present invention relates to a spray dried plasma composition having one or more of the following characteristics: when reconstituted, largely amorphous and has no cholesterol crystals; when reconstituted, the number of large particulates is reduced; has low residual moisture; reconstitutes rapidly in under four minutes; highly stable when stored under refrigeration, at room temperature or at elevated temperatures and allows for storage for longer periods of time; when reconstituted, exhibits recovery of the most fragile of proteins, including von Willebrand's factor; when reconstituted with Sterile Water for Injection (SWFI), reconstituted plasma is at a pH that is near normal plasma pH, and does so without treatment or storage in COor other pH adjustment; and when reconstituted, has reduced complement activation (C5A, C3A).